Michael Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share our preliminary fourth quarter and year end U.S. BRIUMVI net product revenue. As we head into 2024, we have our sights set on achieving revenue and expense targets and have built an ambitious plan to potentially expand the utility of BRIUMVI into new indications and for use as a subcutaneous injection. We are also excited to expand our R&D program with the recent licensing of azer-cel, an allogeneic CD19 CAR T therapy which we believe has the potential to become a meaningful therapy to treat various autoimmune disorders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics announces global license agreement with Precision BioSciences
- Biotech Alert: Searches spiking for these stocks today
- Upcoming Investor Conference Prompts Surge for TG Therapeutics (NASDAQ:TGTX)
- TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- TG Therapeutics call volume above normal and directionally bullish